APPENDIX 7 CLINICAL INSTITUTE NARCOTIC ASSESSMENT (CINA) SCALE FOR WITHDRAWAL SYMPTOMS

Similar documents
Stabilization Algorithm

CMBHS Clinical Management of Behavioral Health Services

Alcohol withdrawal. Clinical features

ALCOHOL WITHDRAWAL GUIDELINES

Taking the pain out of prescribing: An opioid primer for the primary care provider

PPT-PGN-26 Part of NTW(C)38-Pharmacological therapies

Guidelines for Community Detoxification using Buprenorphine.

Lorraine Wilson, 74 years of age, is admitted. Alcohol Withdrawal. During Hospitalization. Early recognition and consistent intervention are critical.

Assessment Main title and management of alcohol dependence and withdrawal in the acute hospital: concise guidance

Initial Patient Assessment Form To be filled out by patient Joseph Park, M.D., F.R.C.P.(C) Anesthesiology & Pain Management

Lead for Gastroenterology Lee Dodge Alcohol Liaison 03/03/2015. Clive Gibson Safeguarding Adults Lead Nurse 03/03/2015

Withdrawal.

Medical Issues for counselors, copy for AATOD conference. In press, Journal of Maintenance in the Addictions Page 1 of 8

Recovery Reintegration. Substance Use Disorder. Resilience. Reintegration. Recovery

MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP

MEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution

MEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution

Alcohol Withdrawal Guidelines

What is the most important information I should know about Morphine Sulfate Oral Solution?

Admit date: 1-WM 2-WM 3.2-WM 3.7-WM 4-WM DSM-V diagnoses: Please list all diagnoses (psychiatric, chemical dependency and medical)

MEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only

MANAGEMENT AND DETOXIFICATION FOR GAMMA- HYDROXYBUTYRATE (GHB) AND GAMMA-BUTARYL LACTONE (GBL) GUIDELINES SEPTEMBER 2017

Alcohol withdrawal including the Symptom triggered CIWA score Management

Opioid Addiction: Hospital Presentations and Management

Provincial Clinical Knowledge Topic Alcohol Withdrawal, Adult Inpatient V 1.0

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Procedure for Tolerance Testing

Identifying Withdrawal and Understanding Detoxification

Buprenorphine Toolkit

Opioids Research to Practice

*521634* Sleep History Questionnaire. Name of primary care doctor:

Controlled Substance and Wellness Agreement

MEDICATION GUIDE CODEINE SULFATE (koh-deen) CII Oral Solution

Medication-Assisted Treatment Of Opioid Use Disorder

Buprenorphine Patch (Transtec Patch)

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

Northern Ireland Alcohol Use Disorders Care Pathway. management in the acute hospital setting

Methotrexate. About This Drug. Possible Side Effects. Warnings and Precautions

Contents. May 2016 KYN Long Training 2

Title Alcohol Withdrawal Management Guidelines

CENTRAL CARE POLICY SYMPTOMS OF ILLNESS. Policy: Consumers will be observed for symptoms of physical problems, distress, pain, or unusual behaviors.

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

Non-prescription Drugs. Wasted Youth

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

ALCOHOL USE DISORDER. Lada Alexeenko, MD

Opioids Research to Practice

MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII)

MEDICALLY ASSISTED COMMUNITY ALCOHOL WITHDRAWAL GUIDELINES SEPTEMBER 2015

Opioids Research to Practice

Opioids Research to Practice

The Limits of Harm Reduction? Neil McKeganey Centre for Substance Use Research West of Scotland Science Park Glasgow Scotland

Medical Necessity Criteria 2017

Problem Summary. * 1. Name

WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS

Northern Ireland Alcohol Use Disorders Care Pathway. management in the acute hospital setting

Behavioral Health Service Request Form Detox and Substance Abuse Rehab

Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers

Headache Follow-up Visit Form

Behavioral Health Service Request Form Detox and Substance Abuse Rehab

Supplemental Digital Content

HEADACHE MEDICINE NEW PATIENT QUESTIONNAIRE

Overview of Psychoactive Drug use

ALLIANCE COMMUNITY HOSPITAL SLEEP DISORDERS CENTER PATIENT QUESTIONNAIRE/HISTORY PLEASE COMPLETE AND BRING WITH YOU ON THE NIGHT OF YOUR TEST.

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)

HISTORY OF PRESENT ILLNESS A. TELL US ABOUT YOUR PAIN PROBLEM

COUPLE & FAMILY INSTITUTE OF TRI-CITIES AMEN ADULT GENERAL SYMPTOM CHECKLIST

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Pharmacological Management of Substance Misuse. Prescribing Guideline

Southeastern Rehabilitation Medicine Initial (New) Outpatient Information Questionnaire

STRUCTURED INTERVIEW GUIDE FOR THE HAMILTON ANXIETY SCALE (SIGH-A) 24 HR TWENTY-FOUR HOUR ASSESSMENT VERSION Janet B.W.

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII)

INFLUENZA (FLU) Cleaning to Prevent the Flu

Drug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment

Painless, progressive weakness Could this be Motor Neurone Disease?

Valium for stomach pain

Tiredness/Fatigue Mild Moderate to severe, especially at onset of symptoms Head and Body Aches and Pains

ACTG Adherence Follow Up Questionnaire

UKnowledge. University of Kentucky. Hannah Young Click here to let us know how access to this document benefits you.

Medical condition SELF Mother Father Sibling (list brother or sister) Anxiety Bipolar disorder Heart Disease Depression Diabetes High Cholesterol

Emotional Relationships Social Life Sexually Recreation

A Prescription for Education. Hillary Dubois, Director of Prevention Services Amanda Sandoval, Asst. Director of Prevention Services

PEDIATRIC PAIN QUESTIONNAIRE Form A (Adolescent)

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

MEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use

Behavioral Health Service Request Form Detox and Substance Abuse Rehab

Understanding Mental Illness A Review of the Disorders

Module II Opioids 101 Opiate Opioid

General Symptoms. Cold Weather Symptoms TG-272

Naloxone Administration Training

Initiation of Medication in Treating Opioid Use Disorder.

For the Patient: Adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab (Herceptin)

SECTION OF NEUROSURGERY PATIENT INFORMATION SHEET

STRUCTURED INTERVIEW GUIDE FOR THE HAMILTON ANXIETY SCALE (SIGH-A) Janet B.W. Williams, D.S.W.

Patient Information Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets

PATIENT INFORMATION LEAFLET SINTAIR RANGE

BRAIN STEM CASE HISTORIES CASE HISTORY VII

Indiana Polyclinic Combined Pain Scale Rate your pain according to the following scale Examples

Share the important information in this Medication Guide with members of your household.

Transcription:

APPENDIX 7 CLINICAL INSTITUTE NARCOTIC ASSESSMENT (CINA) SCALE FOR WITHDRAWAL SYMPTOMS The Clinical Institute Narcotic Assessment (CINA) Scale measures 11 signs and symptoms commonly seen in patients during narcotic withdrawal. This can help to gauge the severity of the symptoms and to monitor changes in the clinical status over time. Minimum score = 0, Maximum score = 1. The higher the score, the more severe the withdrawal syndrome. Percent of maximal withdrawal symptoms = total score/1 x 100%. Source: Adapted from Peachey JE, Lei H. Assessment of opioid dependence with naloxone. Br J Addict. 1988 Feb;8():19-01. PREGNANCY AND OPIOID EXPOSURE: GUIDANCE FOR NORTH CAROLINA

Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) Patient: Date: Time: (4 hour clock, midnight = 00:00) Pulse or heart rate, taken for one minute: Blood pressure: NAUSEA AND VOMITING -- Ask "Do you feel sick to your stomach? Have you vomited?" Observation. 0 no nausea and no vomiting 1 mild nausea with no vomiting 4 intermittent nausea with dry heaves 7 constant nausea, frequent dry heaves and vomiting TREMOR -- Arms extended and fingers spread apart. Observation. 0 no tremor 1 not visible, but can be felt fingertip to fingertip 4 moderate, with patient's arms extended 7 severe, even with arms not extended PAROXYSMAL SWEATS -- Observation. 0 no sweat visible 1 barely perceptible sweating, palms moist 4 beads of sweat obvious on forehead 7 drenching sweats ANXIETY -- Ask "Do you feel nervous?" Observation. 0 no anxiety, at ease 1 mild anxious 4 moderately anxious, or guarded, so anxiety is inferred 7 equivalent to acute panic states as seen in severe delirium or acute schizophrenic reactions TACTILE DISTURBANCES -- Ask "Have you any itching, pins and needles sensations, any burning, any numbness, or do you feel bugs crawling on or under your skin?" Observation. 0 none 1 very mild itching, pins and needles, burning or numbness mild itching, pins and needles, burning or numbness moderate itching, pins and needles, burning or numbness 4 moderately severe hallucinations severe hallucinations extremely severe hallucinations 7 continuous hallucinations AUDITORY DISTURBANCES -- Ask "Are you more aware of sounds around you? Are they harsh? Do they frighten you? Are you hearing anything that is disturbing to you? Are you hearing things you know are not there?" Observation. 1 very mild harshness or ability to frighten mild harshness or ability to frighten moderate harshness or ability to frighten 4 moderately severe hallucinations severe hallucinations extremely severe hallucinations 7 continuous hallucinations VISUAL DISTURBANCES -- Ask "Does the light appear to be too bright? Is its color different? Does it hurt your eyes? Are you seeing anything that is disturbing to you? Are you seeing things you know are not there?" Observation. 1 very mild sensitivity mild sensitivity moderate sensitivity 4 moderately severe hallucinations severe hallucinations extremely severe hallucinations 7 continuous hallucinations HEADACHE, FULLNESS IN HEAD -- Ask "Does your head feel different? Does it feel like there is a band around your head?" Do not rate for dizziness or lightheadedness. Otherwise, rate severity. 1 very mild mild moderate 4 moderately severe severe very severe 7 extremely severe

AGITATION -- Observation. 0 normal activity 1 somewhat more than normal activity 4 moderately fidgety and restless 7 paces back and forth during most of the interview, or constantly thrashes about ORIENTATION AND CLOUDING OF SENSORIUM -- Ask "What day is this? Where are you? Who am I?" 0 oriented and can do serial additions 1 cannot do serial additions or is uncertain about date disoriented for date by no more than calendar days disoriented for date by more than calendar days 4 disoriented for place/or person Total CIWA-Ar Score Rater's Initials Maximum Possible Score 7 The CIWA-Ar is not copyrighted and may be reproduced freely. This assessment for monitoring withdrawal symptoms requires approximately minutes to administer. The maximum score is 7 (see instrument). Patients scoring less than 10 do not usually need additional medication for withdrawal. Sullivan, J.T.; Sykora, K.; Schneiderman, J.; Naranjo, C.A.; and Sellers, E.M. Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). British Journal of Addiction 84:1-17, 1989.

Clinical Institute Withdrawal Assessment Scale - Benzodiazepines Guide to the Use of the Clinical Withdrawal Assessment Scale for Benzodiazepines Person Report: For each of the following items, circle the number that best describes how you feel. W$C$.=")//)*1H"q W$C$.="=1*)7.q W$C$.="*+0q W$C$.%1:)==)#."*)0 #$+#+*/1*)+7q W$C$.%1:1+C"$00$= 1*)*q M1:C$.1+C+.GH+00$/ H./+)+7$+C$./=1#F%1+0 $/=*q W$C$.="C$./%1/*/1#)+7q 1")*1*)$+0; W$0C$./%1="=.""$/ 1#%Cq Q \$*1*1"" Q \$*1*1"" Q \$*1*1"" Q \$*1*1"" Q \$*1*1"" Q \$ +.GH+00 Q \$ )0*./H1+# Q \$*1*1"" ', @ - s/cg.#%0$ ', @ - `+1H"*$=.+#*)$+ ', @ - s/cg.#%0$ ', @ - ', @ - ', @ - ', @ - ', @ - `+1H"*$ #$+#+*/1* \$1*)*F.+1H" *$1* V+*+0 H./+)+7N+.GH+00 U$+0*1+*/1#)+7 S:/%11#%

W$C$.="G.0#"1#%0$/ 0*)==+00q W$C$.="1+E)$.0F+/:$.0 $/d)**/cq W$C$.=".0*q M$D/0*=."D10C$./0" "10*+)7%*q W$C$.="D1>q W$C$.*%)+>C$.)+t*%1: +$.7%0""10*+)7%*q W$C$.%1:1+C:)0.1" )0*./H1+#0q0+0)*):)*C*$ ")7%*FH".//:)0)$+;!/C$.=1/=."q M1:C$.H+D$//C)+7 1H$.*$00)H"G)0=$/*.+0 "1*"Cq Q \$*1*1"" Q \$*1*1"" Q \$*1*1"" Q s/c/0*=." Q \$*1*1"" Q s/cg.#% 0$ Q \$*1*1"" Q \$*1*1"" Q \$*1*1"" ', @ - ', @ - ', @ - ', @ - ', @ - ', @ - ', @ - ', @ - ', @ - S:/0*)==+00$/ 1)+ s/cg.#%0$ s/cg.#%0$ \$*1*1"" s/cg.#%0$ \$*1*1"" s/c0+0)*):*$ ")7%*FH".//:)0)$+ s/cg.#%0$ s/cg.#%0$

Clinician Observations Observe behaviour for sweating, restlessness and agitation Observe tremor Observe feel palms Q \$+F+$/G1"1#*):)*C Q \$*/G$/ Q \$0D1*)+7:)0)H" ', @ - ]0*"00 P1#0H1#>1+ =$/*%F.+1H"*$0)* 0*)"" ', @ - \$*:)0)H"F#1+H="*)+ =)+7/0 s)0)h"h.*g)" R$/1*D)*%1/G0 E*+ S:/FD)*%1/G0+$* E*+ ', @ - 81/"C/#*)H" 0D1*)+7F1"G0G$)0* P1"G01+=$/%1 G$)0*F/$/*01/G)* 0D1*)+7 810$=0D1*$+ =$/%1 S://+#%)+7 0D1*0 Total Score Items 1 0 1 0 = mild withdrawal 41 0 = severe withdrawal 1 40 =moderate withdrawal 1 80 = very severe withdrawal Source: Adapted from Busto, U.E., Sykora, K. Sellers, E.M. (1989). A clinical scale to assess benzodiazepine withdrawal. Journal of Clinical Psychopharmacology, 9 (), 41 41.

Clinical Opiate Withdrawal Scale Introduction The Clinical Opiate Withdrawal Scale (COWS) is an 11-item scale designed to be administered by a clinician. This tool can be used in both inpatient and outpatient settings to reproducibly rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time. The summed score for the complete scale can be used to help clinicians determine the stage or severity of opiate withdrawal and assess the level of physical dependence on opioids. Practitioners sometimes express concern about the objectivity of the items in the COWS; however, the symptoms of opioid withdrawal have been likened to a severe influenza infection (e.g., nausea, vomiting, sweating, joint aches, agitation, tremor), and patients should not exceed the lowest score in most categories without exhibiting some observable sign or symptom of withdrawal. http://www.drugabuse.gov/nidamed-medical-health-professionals

Wesson Ling Clinical Opiate Withdrawal Scale APPENDIX 1 Clinical Opiate Withdrawal Scale For each item, circle the number that best describes the patient' s signs or symptom. Rate on just the apparent relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior to assessment, the increase pulse rate would not add to the score. Patient's Name: Date and Time _!!_ Downloaded by [HSRL - Health Science Research Library] at 14:04 0 September 01 Reason for this assessment: Resting Pulse Rate: beats/minute Measured after patient is sitting or lying fo r one minute 0 pulse rate 80 or below 1 pulse rate 81-100 pulse rate 101-10 4 pulse rate greater than 10 Sweating: over past 1/ hour not accounted for by room temperature or patient activity. 0 no report of chills or flushing 1 subjective report of chills or flushing flushed or observable moistness on face beads of sweat on brow or face 4 sweat streaming off face Restlessness Observation during assessment 0 able to sit still 1 reports difficulty sitting still, but is able to do so frequent shifting or extraneous movements of legs/arms unable to sit still for more than a few seconds Pupil size 0 pupils pinned or normal size for room light 1 pupils possibly larger than normal for room light pupils moderately dilated pupils so dilated that only the rim of the iris is visible Bone or Joint aches if patient was having pain previously, only the additional component attributed to opiates withdrawal is scored 1 mild diffuse discomfort patient reports severe diffuse aching of joints/muscles 4 patient is rubbing joints or muscles and is unable to sit still because of discomfort Runny nose or tearing Not accounted fo r by cold -symptoms or allergies 1 nasal stuffiness or unusually moist eyes nose running or tearing 4 nose constantly running or tears streaming down cheeks GI Upset: over last 1/ hour 0 no GI symptoms 1 stomach cramps nausea or loose stool vomiting or diarrhea multiple episodes of diarrhea or vomiting Tremor observation of outstretched hands 0 no tremor 1 tremor can be felt, but not observed slight tremor observable 4 gross tremor or muscle twitching Yawning Observation during assessment 0 no yawning 1 yawning once or twice during assessment yawning three or more times during assessment 4 yawning several times/minute Anxiety or Irritability 0 none 1 patient reports increasing irritability or anxiousness patient obviously irritable or anxious 4 patient so irritable or anxious that participation in the assessment is difficult Gooseflesh skin 0 skin is smooth piloerrection of skin can be felt or hairs standing up on arms prominent piloerrection Initials of person completing assessment: Total Score The total score is the sum of all 11 items Score: - 1 = mild; 1-4 = moderate; - = moderately severe; more than = severe withdrawal This version may be copied and used clinically. Journal of Psychoactive Drugs Volume (), April - June 00 Source: Wesson, D. R., Ling, W. (00). The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs, (), 9.